Evidence map›Paper›PMID 32079107›Full record

ArticleCancers2020

An Epitope on EGFR Loading Catastrophic Internalization Serve as a Novel Oncotarget for Hepatocellular Carcinoma Therapy.

Dianshuai Huang, Qingjie Fan, Zhiyi Liu, Shuqin Zhang, Wei Huang, Hongrui Li, Chongyang Liang, Fei Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Recent Advances in the Use ofPharmaceutics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dianshuai HuangInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Qingjie FanDepartment of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, Jilin, China.
Zhiyi LiuInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Shuqin ZhangInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Wei HuangInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Hongrui LiInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Chongyang LiangInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Fei SunInstitute of Frontier Medical Science, Jilin University, Changchun 130021, Jilin, China.
Jilin University · CN

Funding

National Natural Science Foundation of China 31271478National Natural Science Foundation of China 81202446
6 · The paper itself

Abstract

The precise role of Epidermal Growth Factor Receptor (EGFR) in Hepatocellular carcinoma (HCC) cells is unknown and EGFR inhibitors have not achieved positive clinical results. The rapid and drastic internalization of EGFR has been proved to successfully treat EGFR inhibitor-resistant patients in recent clinical trials. Here, the anti-tumor efficacy of a protein (rLZ-8) from

Indexed as

EGFRepitopeHCCinternalizationtarget therapy

Identifiers

PMID32079107
PMCPMC7072198
OpenAlexW3005560042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.